Acquisitions Drive 13-Percent Q3 Revenue Growth for Invitrogen, But Profit Falls | GenomeWeb

NEW YORK, Oct. 28 (GenomeWeb News) - Invitrogen yesterday reported a 13-percent year-over year increase in third-quarter revenues, of which 12 percent was attributed to acquisitions. The company posted a 15-percent decrease in net income, however, related to its recent purchase of Dynal Biotech.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.